Protection against Leishmania major infection by oligomannose-coated liposomes

Shimizu, Yoshitaka; Yamakami, Kazuo; Gomi, Takao; Nakata, Munehiro; Asanuma, Hideki; Tadakuma, Takushi; Kojima, Naoya

doi:10.1016/s0968-0896(02)00644-2

Cited by 42 publications

(35 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The neoglycolipids were prepared by conjugation of these oligosaccharides with DPPE by reductive amination as described previously (36). In brief, 20 Amol of the oligosaccharide and 70 Amol DPPE were dissolved in 5 mL chloroform/methanol/water (10:10:1, v/v/v).…”

Section: Methodsmentioning

confidence: 99%

A Carbohydrate Recognition–Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle

et al. 2006

Self Cite

View full text Add to dashboard Cite

The lymphoid tissue in the omentum, at the so-called milky spots, is known as an initial place for disseminated cancer cells to develop into solid tumors. In the present study, i.p. macrophages significantly took up oligomannose-coated liposomes (OMLs) that were injected into the peritoneal cavity, and then gradually accumulated in the omentum and the other lymphoid tissues within 24 hours of i.p. injection of OMLs. When 5-fluorouracil (5-FU) was encapsulated in the OMLs, >60% of administered 5-FU accumulated in the omentum. Treatment of macrophages at 39°C for 30 minutes led to the release of 5-FU from the macrophages, suggesting that controlled release from macrophages could be achieved by mild hyperthermia. We encased magnetic nanoparticles, which are known to convert electromagnetic energy to heat in the OMLs to achieve in vivo hyperthermia at the site. Using this system in a mouse i.p. metastasis model, we successfully controlled tumor development by coadministration of OML-encased 5-FU and OML-encased magnetic nanoparticles, followed by treatment with an alternating magnetic field. No apparent reduction was seen in tumor growth with the administration of OML-encased magnetic nanoparticles or OML-encased 5-FU alone. Thus, we have established the use of i.p. macrophages as a novel drug delivery system for the control of cancer metastatic to milky spots. (Cancer Res 2006; 66(17): 8740-8)

show abstract

Section: Methodsmentioning

confidence: 99%

A Carbohydrate Recognition–Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle

et al. 2006

Self Cite

View full text Add to dashboard Cite

show abstract

“…79,80 A liposomal SLA formulation consisting of DPPC, cholesterol, and mannopentaose-dipalmitoylphosphatidylethanolamine (Man5-DPPE) was prepared to study its protective response in BALB/c mice against leishmaniasis. 60 The Man5-DPPE is a synthesized neoglycolipid which can interact with mannose receptors on the surface of APCs. Man5-DPPE-coated liposomes induced protection against leishmanial infection compared with noncoated liposomes.…”

Section: Effect Of Active Targeting To Antigen Presenting Cellsmentioning

confidence: 99%

“…As their adjuvanticity is due to an efficient carbohydrate-protein interaction through the mannose receptor, it is much stronger and more specific than interaction by charge. 60 The coupling of target-specific antibodies to the liposomal surface to create immunoliposomes has appeared as a promising way to achieve active targeting of liposomes. In a study, immunoliposomes were prepared by grafting nonimmune mouse IgG onto the liposomal surface.…”

Section: Effect Of Active Targeting To Antigen Presenting Cellsmentioning

confidence: 99%

Liposomal adjuvant development for leishmaniasis vaccines

Askarizadeh

Jaafari

Khamesipour

et al. 2017

Therapeutic Advances in Vaccines

View full text Add to dashboard Cite

Leishmaniasis is a parasitic disease that ranges in severity from skin lesions to fatality. Since long-lasting protection is induced upon recovery from cutaneous leishmaniasis, development of an effective vaccine is promising. However, there is no vaccine for use in humans yet. It seems limited efficacy in leishmaniasis vaccines is due to lack of an appropriate adjuvant or delivery system. Hence, the use of particulate adjuvants such as liposomes for effective delivery to the antigen presenting cells (APCs) is a valuable strategy to enhance leishmaniasis vaccine efficacy. The extraordinary versatility of liposomes because of their unique amphiphilic and biphasic nature allows for using antigens or immunostimulators within the core, on the surface or within the bilayer, and modulates both the magnitude and the T-helper bias of the immune response. In this review article, we attempt to summarize the role of liposomal adjuvants in the development of Leishmania vaccines and describe the main physicochemical properties of liposomes like phospholipid composition, surface charge, and particle size during formulation design. We also suggest potentially useful formulation strategies in order for future experiments to have a chance to succeed as liposomal vaccines against leishmaniasis.

show abstract

“…Qualitative studies on Leishmania antigens on immunoblots have demonstrated preferential recognition of Leishmania infantum, Leishmania donovani, and L. major antigens by a particular subclass of antibodies (Shimizu et al, 2003;Iborra et al, 2004;Lange et al, 2004;Tewary et al, 2004). The isotype profile of antibody responses depends on the cytokines produced by antigen specific T-cells.…”

mentioning

confidence: 99%